BR112013026706A2 - composições nutricionais compreendendo ácido alfa-hidroxi-isocaproico - Google Patents

composições nutricionais compreendendo ácido alfa-hidroxi-isocaproico

Info

Publication number
BR112013026706A2
BR112013026706A2 BR112013026706A BR112013026706A BR112013026706A2 BR 112013026706 A2 BR112013026706 A2 BR 112013026706A2 BR 112013026706 A BR112013026706 A BR 112013026706A BR 112013026706 A BR112013026706 A BR 112013026706A BR 112013026706 A2 BR112013026706 A2 BR 112013026706A2
Authority
BR
Brazil
Prior art keywords
nutritional compositions
alpha hydroxy
nutritional
isocaproic acid
methods
Prior art date
Application number
BR112013026706A
Other languages
English (en)
Portuguese (pt)
Inventor
Denis Breuille
Doug Bolster
Jennifer Mager
Norman Alan Greenberg
Zamzam Fariba Roughead
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of BR112013026706A2 publication Critical patent/BR112013026706A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E10/00—Energy generation through renewable energy sources
    • Y02E10/70—Wind energy
    • Y02E10/72—Wind turbines with rotation axis in wind direction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pediatric Medicine (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
BR112013026706A 2011-04-18 2012-04-18 composições nutricionais compreendendo ácido alfa-hidroxi-isocaproico BR112013026706A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161476345P 2011-04-18 2011-04-18
PCT/EP2012/057092 WO2012143402A1 (en) 2011-04-18 2012-04-18 Nutritional compositions comprising alpha-hydroxyisocaproic acid

Publications (1)

Publication Number Publication Date
BR112013026706A2 true BR112013026706A2 (pt) 2016-12-27

Family

ID=45976400

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112013026539A BR112013026539A2 (pt) 2011-04-18 2012-04-18 composições nutricionais que têm a-hica e a-cetoglutarato e métodos de uso das mesmas
BR112013026706A BR112013026706A2 (pt) 2011-04-18 2012-04-18 composições nutricionais compreendendo ácido alfa-hidroxi-isocaproico

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112013026539A BR112013026539A2 (pt) 2011-04-18 2012-04-18 composições nutricionais que têm a-hica e a-cetoglutarato e métodos de uso das mesmas

Country Status (13)

Country Link
US (4) US20140056862A1 (enExample)
EP (4) EP2699112A1 (enExample)
JP (4) JP2014511890A (enExample)
CN (4) CN103476274A (enExample)
AU (4) AU2012244751A1 (enExample)
BR (2) BR112013026539A2 (enExample)
CA (4) CA2831001A1 (enExample)
MX (4) MX2013012228A (enExample)
PH (4) PH12013501927A1 (enExample)
RU (4) RU2013151087A (enExample)
SG (4) SG194028A1 (enExample)
WO (4) WO2012143403A1 (enExample)
ZA (4) ZA201308607B (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2583566B1 (en) * 2011-10-21 2015-08-19 Nestec S.A. Whey protein micelles to enhance muscle mass and performance
EP2583563A1 (en) * 2011-10-21 2013-04-24 Nestec S.A. Whey protein micelles against muscle atrophy and sarcopenia
ITBO20120226A1 (it) * 2012-04-24 2013-10-25 Alfa Wassermann Spa Composizioni comprendenti ornitina alfa-chetoglutarato, processi per il loro ottenimento e il loro uso.
CN103783532B (zh) * 2012-10-29 2016-06-08 杭州纽曲星生物科技有限公司 一种抗老年性肌肉衰减的复合蛋白质粉及其制备方法
CN105120689A (zh) * 2013-04-15 2015-12-02 雀巢产品技术援助有限公司 乳清蛋白质与电肌肉刺激组合的用途
CN112931879A (zh) * 2013-06-10 2021-06-11 N·V·努特里奇亚 超重或肥胖成年人在体重减轻项目期间的肌肉保持
MX2016003944A (es) * 2013-09-25 2016-12-09 Pronutria Biosciences Inc Composiciones y formulaciones para mantener y aumentar la masa muscular, fuerza y rendimiento y metodos de produccion y usos de los mismos.
BR112016007487A2 (pt) 2013-10-09 2017-08-01 Nestec Sa composições compreendendo citrulina e leucina e seu uso no tratamento de diabetes e de síndrome meta-bólica
CN103637212B (zh) * 2013-12-13 2014-12-24 广东省农业科学院蚕业与农产品加工研究所 一种具有降血脂作用的管饲临床营养品及其制备方法
WO2015133627A1 (ja) * 2014-03-07 2015-09-11 味の素株式会社 虚弱予防剤
WO2015137387A1 (ja) * 2014-03-11 2015-09-17 協和発酵バイオ株式会社 筋肉増強剤
MX2016012427A (es) * 2014-03-26 2017-04-27 Abbott Lab Suplemento alimenticio en polvo.
WO2015151066A1 (en) * 2014-04-04 2015-10-08 Polifenoles Naturales, S.L. Treatment of sarcopenia with ecdysteroids
WO2015160262A1 (en) * 2014-04-16 2015-10-22 Amerikal Nutraceutical Corp Anti-aging composition
US20170196243A1 (en) * 2014-06-03 2017-07-13 Abbott Laboratories Potato based protein mixtures and nutritional compositions comprising potato protein
US11102994B2 (en) 2014-08-21 2021-08-31 Clearfast Inc. Pre-operative carbohydrate-rich beverage composition and methods of treatment
WO2016044167A1 (en) * 2014-09-15 2016-03-24 Abbott Laboratories Methods for increasing muscle strength and mobility in subjects experiencing significant physical inactivity using gamma linolenic acid
ES2960218T3 (es) * 2014-10-14 2024-03-01 Nestle Sa Mejora en la funcionalidad del músculo de hombres ancianos
US11040022B2 (en) * 2015-02-05 2021-06-22 William H. Cross, III Compositions and methods for pain relief
NL2015032B1 (en) * 2015-06-26 2017-01-24 Vitalnext B V Compositions and methods for the treatment of malnutrition.
US10674746B2 (en) 2015-10-27 2020-06-09 Cytozyme Animal Nutrition, Inc. Animal nutrition compositions and related methods
BR112018007434A2 (pt) 2015-10-27 2018-10-23 Cytozyme Animal Nutrition Inc composições para nutrição animal, usos e métodos relacionados
RU2614881C1 (ru) * 2015-12-29 2017-03-30 Общество с ограниченной ответственностью "Мобильный доктор" Комплекс биологически активных веществ, защищающих спортсменов от перетренированности
WO2017114686A1 (en) * 2015-12-30 2017-07-06 Nestec S.A. Method for determining fat free body mass
WO2017151540A1 (en) 2016-02-29 2017-09-08 Abbott Laboratories Nutritional supplement powder
US11612632B2 (en) 2017-04-25 2023-03-28 William H. Cross, III Compositions and methods for treatment of prediabetes
PL3458046T3 (pl) * 2016-05-20 2021-07-05 Société des Produits Nestlé S.A. Triglicerydy o średniej długości łańcucha do leczenia zwyrodnieniowej choroby zastawki mitralnej u zwierząt towarzyszących
CN106213522A (zh) * 2016-08-05 2016-12-14 郑家福 营养保健品
RU2635373C1 (ru) * 2016-08-25 2017-11-13 Федеральное государственное бюджетное образовательное учреждение высшего образования "Национальный исследовательский Мордовский государственный университет им. Н.П. Огарёва" Биологически активная добавка для повышения общей работоспособности
CN117959415A (zh) 2016-09-13 2024-05-03 阿勒根公司 非蛋白质梭菌毒素组合物
BR112019009757B1 (pt) * 2016-11-16 2022-12-20 Fresenius Kabi Deutschland Gmbh Pufa, vitamina e, vitamina d e os aminoácidos ligados às proteínas glicina, arginina e triptofano, seu uso na fabricação de uma composição nutricional para tratar sarcopenia e/ou fraqueza e composição nutricional
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
KR20180081361A (ko) * 2017-01-06 2018-07-16 연세대학교 산학협력단 인돌-3-카비놀 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 근육 질환 예방 또는 치료용 조성물
US12213952B1 (en) 2017-03-09 2025-02-04 Heh Research & Development Services, Inc. Biologic enhancement formulation
WO2020106746A1 (en) 2018-11-19 2020-05-28 Heh Research & Development Services, Inc. Biologic enhancement formulation
KR102805246B1 (ko) * 2017-04-25 2025-05-09 버크 인스티튜트 포 리서치 온 에이징 수명 및 건강수명을 연장시키기 위한 제제
US11260088B2 (en) 2017-06-21 2022-03-01 Abbott Laboratories Methods for increasing growth of beneficial bacteria in the gastrointestinal tract
CN107242572A (zh) * 2017-07-06 2017-10-13 广州彤博士健康科技有限公司 营养补充剂及制备方法
CN111295187A (zh) 2017-08-14 2020-06-16 胺细拉健康公司 用于治疗肝脏疾病的氨基酸组合物
CN107616505B (zh) * 2017-10-24 2020-12-25 精晶药业股份有限公司 一种含有鸟氨酸酮戊二酸的保健品及其制备方法
PL238310B1 (pl) * 2017-10-31 2021-08-09 Top Energy Set Spolka Z Ograniczona Odpowiedzialnoscia Preparat leczniczy oraz sposób jego uzyskiwania
US11154523B2 (en) 2018-01-31 2021-10-26 William H. Cross, III Compositions and methods for treatment of diabetic neuropathies
US11351188B2 (en) 2018-01-31 2022-06-07 William H. Cross, III Folic compositions and methods for treatment of diabetic neuropathies
US11304971B2 (en) 2018-01-31 2022-04-19 William H. Cross, III Metformin compositions and methods for treatment of diabetes
US12329818B2 (en) 2018-02-22 2025-06-17 William H. Cross, III Topical compositions and methods for treatment of diabetic neuropathies
MA52971A (fr) 2018-06-20 2021-04-28 Axcella Health Inc Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle
US11802103B2 (en) 2018-09-25 2023-10-31 Ponce De Leon Health Designated Activity Company Process of making calcium alpha-ketoglutarate
KR102171518B1 (ko) * 2019-02-21 2020-10-29 한양대학교 에리카산학협력단 지골피 추출물을 유효성분으로 함유하는 근 위축 예방 또는 치료용 조성물
CA3140992A1 (en) * 2019-05-31 2020-12-03 Societe Des Produits Nestle Sa Mct-based nutrition blend for providing health benefits in animals
JP2022536653A (ja) * 2019-06-10 2022-08-18 バック インスティチュート フォー リサーチ オン エージング 老化関連分泌表現型を修整する方法および組成物
CN110226756A (zh) * 2019-06-18 2019-09-13 山东理工大学 预防和缓解2型糖尿病患者肌少症的蛋白组件及制备方法
TWI774966B (zh) * 2019-06-25 2022-08-21 生合生物科技股份有限公司 胚芽乳桿菌bcrc 910734用於提升老年個體的肌力以及治療肌肉減少症的用途
US11969502B2 (en) 2019-12-09 2024-04-30 Nicoventures Trading Limited Oral products
US11872231B2 (en) 2019-12-09 2024-01-16 Nicoventures Trading Limited Moist oral product comprising an active ingredient
WO2021133962A1 (en) * 2019-12-27 2021-07-01 Grove Collaborative, Inc. Confections for skin protection: compositions, methods for making, and applications thereof
US20230148618A1 (en) * 2020-03-30 2023-05-18 Compagnie Gervais Danone Fermented milk compositions for use in methods of nutritional supplementation
CN114786502A (zh) * 2020-04-03 2022-07-22 三菱瓦斯化学株式会社 肌肉增强剂
EP4175978A4 (en) * 2020-07-02 2024-06-26 Ponce de Leon Health Designated Activity Company COMPOSITIONS AND METHODS FOR TREATING CRP-MEDIATED DISEASES
WO2022040129A1 (en) * 2020-08-18 2022-02-24 Foodscience Corporation Polymerized whey protein encapsulated antioxidant compound and a process for preparation of same
FI129515B (en) * 2020-11-06 2022-03-31 Salarusta Oy FOR USE IN THE PREVENTION AND / OR TREATMENT OF A DISEASE OR CONDITION RELATED TO THE DEGRADATION AND / OR DISTURBANCE OF THE DEGREE OF MONTOOSASE AND / OR INTEGRITY
CN112899204B (zh) * 2021-03-19 2022-06-28 杭州百芮生物科技有限公司 一种益生菌冻干外壳复合保护剂及其应用
CN113398144B (zh) * 2021-07-27 2022-04-01 陈玉松 核苷酸混合物在制备预防或缓解老年肌少症制剂中的应用
CN114029085B (zh) * 2021-12-06 2024-02-27 中触媒新材料股份有限公司 一种烯烃环氧化催化剂及其制备方法和应用
WO2023121696A1 (en) * 2021-12-20 2023-06-29 Schneider Todd C Formulation and treatment for extended micronutrient therapy
WO2025151881A1 (en) * 2024-01-12 2025-07-17 Heh Research & Development Services, Inc. Biologic enhancement formulation

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2335215B2 (de) * 1972-07-13 1979-04-05 The Johns Hopkins University, Baltimore, Md. (V.St.A.) Verwendung einer Mischung bei der Bekämpfung von zur Urämie führenden Nierenerkrankungen
GB1444621A (en) * 1973-04-30 1976-08-04 Walser M Composition for promotion of protein synthesis and suppression of urea formation in the body utilizing alpha-hydroxy-acid analogues of amino acids
GB1442154A (en) * 1973-04-30 1976-07-07 Walser M Composition for promotion of protein synthesis and suppression of urea formation in the body
GB1511302A (en) * 1974-04-15 1978-05-17 Univ Johns Hopkins Pharmaceutical compositions comprising amino acid analogues
US4752619A (en) 1985-12-23 1988-06-21 The Johns Hopkins University Nutritional supplement for treatment of uremia
SE8803144L (sv) * 1988-09-07 1990-03-08 Kabivitrum Ab Energisubstrat
SE9201584D0 (sv) * 1992-05-20 1992-05-20 Vinnars Erik Ab Use of alpha-ketoglutarate
US5646187A (en) * 1992-05-20 1997-07-08 Ab Erik Vinnars Use of alpha-ketoglutarate
SE0201713D0 (sv) * 2001-11-23 2002-06-06 Gramineer Internat Ab New methods and use III
US20040087490A1 (en) * 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
US8795693B2 (en) * 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
WO2005107735A2 (en) * 2004-04-30 2005-11-17 Pump Formulations, Ltd. Nutritional composition for enhancing lean muscle stimulus, growth, strength and recovery, creating and prolonging intense muscle pumps, supporting endurance, strength, performance, size and stamina, providing a transducer effect for nitric oxide, incresing nutrient delivery and/or promoting increased vascular response in a
FI20045395L (fi) * 2004-10-21 2006-04-22 Elmomed Ltd Oy Ravintoainelisä ja sen käyttö
CN101179943B (zh) * 2005-05-23 2013-06-26 卡夫食品环球品牌有限责任公司 填充液体的咀嚼型胶基糖组合物
JP4750184B2 (ja) * 2005-05-23 2011-08-17 キャドバリー アダムス ユーエスエー エルエルシー 味覚増強組成物並びに味覚増強組成物を含有する、食用菓子製品及びチューインガム製品
EP1774973A1 (en) * 2005-10-12 2007-04-18 Nutricia N.V. Leucine rich composition
WO2007053943A1 (en) * 2005-11-08 2007-05-18 Multi Formulations Ltd. The use of compositions comprising ketoacids and amino acids for increasing muscle mass and muscle performance
ES2332149T3 (es) * 2005-12-16 2010-01-27 N.V. Nutricia Composicion comprendiendo oligosacaridos en forma de fibras dieteticas solubles para su uso contra la atrofia muscular.
CN101371142A (zh) * 2006-01-19 2009-02-18 安特瑞斯公司 诊断方法和治疗方法
JP2009527504A (ja) * 2006-02-23 2009-07-30 イオメディックス スリープ インターナショナル エスアールエル 良質な睡眠の誘導および維持のための組成物および方法
CN101437410A (zh) * 2006-03-23 2009-05-20 雀巢产品技术援助有限公司 高热量营养添加剂
EP2679223A1 (en) * 2006-04-04 2014-01-01 Nestec S.A. Treatments using citrulline
CN101415414B (zh) * 2006-04-04 2013-06-12 雀巢产品技术援助有限公司 瓜氨酸在制备治疗矫正脓毒症患者中精氨酸缺乏的药物中的用途
PL379512A1 (pl) * 2006-04-21 2007-10-29 Sgp & Sons Ab Nowe metody i ich zastosowanie
WO2008018043A2 (en) * 2006-08-09 2008-02-14 The Iams Company Methods of improving bone health and muscle health
FR2913885B1 (fr) * 2007-03-22 2012-07-20 Univ Paris Descartes Utilisation de la citrulline pour le traitement des pathologies liees a une augmentation de la carbonylation des proteines
EP2192898A1 (en) * 2007-09-11 2010-06-09 Northern Innovations And Formulations Corp. Composition and method for increasing the anabolic state of muscle cells
US20090156647A1 (en) * 2007-12-12 2009-06-18 Iovate T. & P. Inc. Method for maintaining physiological pH levels during intensive physical exercise
CA2610820A1 (en) * 2007-12-12 2008-12-29 Michele Molino Method for maintaining physiological ph levels during intensive physical exercise
WO2010002242A1 (en) * 2008-07-02 2010-01-07 N.V. Nutricia Nutritional composition for improving muscle function and daily activity
JP2010105946A (ja) * 2008-10-29 2010-05-13 Nof Corp 筋タンパク質増強剤及びこれを含む医薬品または食品
US20120178672A1 (en) * 2009-03-18 2012-07-12 Wolfe Robert R Compositions and Methods for Sparing Muscle in Renal Insufficiency and During Hemodialysis
WO2010137944A1 (en) * 2009-05-27 2010-12-02 N.V. Nutricia Treatment of hypercalcaemia
RU2012105901A (ru) * 2009-07-20 2013-08-27 Нестек С.А. Способы снижения потери функционального состояния
CN102481009A (zh) * 2009-08-13 2012-05-30 雀巢产品技术援助有限公司 包含外源性核苷酸的营养组合物
JP2013504572A (ja) * 2009-09-14 2013-02-07 ネステク ソシエテ アノニム 外因性ビタミンｋ２を含む炎症調節用栄養組成物

Also Published As

Publication number Publication date
MX2013012229A (es) 2013-12-06
WO2012143402A1 (en) 2012-10-26
CA2832150A1 (en) 2012-10-26
CN103476274A (zh) 2013-12-25
WO2012143405A1 (en) 2012-10-26
CN103458710A (zh) 2013-12-18
AU2012244749A1 (en) 2013-10-10
JP2014511890A (ja) 2014-05-19
PH12013502027A1 (en) 2013-12-16
CA2831165A1 (en) 2012-10-26
AU2012244751A1 (en) 2013-10-17
RU2013151083A (ru) 2015-05-27
AU2012244748B2 (en) 2016-07-14
PH12013502027B1 (en) 2019-03-22
CN103491804A (zh) 2014-01-01
CA2831001A1 (en) 2012-10-26
SG193933A1 (en) 2013-11-29
ZA201308607B (en) 2015-05-27
EP2699111A1 (en) 2014-02-26
ZA201308606B (en) 2015-05-27
WO2012143404A1 (en) 2012-10-26
EP2699112A1 (en) 2014-02-26
JP2014512371A (ja) 2014-05-22
MX2013012228A (es) 2013-12-06
MX2013012231A (es) 2014-06-05
SG194028A1 (en) 2013-11-29
ZA201308604B (en) 2015-05-27
US20140044685A1 (en) 2014-02-13
SG193938A1 (en) 2013-11-29
US20140037604A1 (en) 2014-02-06
RU2013151085A (ru) 2015-05-27
WO2012143403A1 (en) 2012-10-26
AU2012244750A1 (en) 2013-10-17
EP2699110A1 (en) 2014-02-26
PH12013501927A1 (en) 2013-10-14
PH12013502012A1 (en) 2019-03-22
JP2014512372A (ja) 2014-05-22
PH12013501926A1 (en) 2013-10-14
MX2013012230A (es) 2014-06-05
ZA201308605B (en) 2015-05-27
CA2832507A1 (en) 2012-10-26
US20140056863A1 (en) 2014-02-27
RU2013151090A (ru) 2015-05-27
SG194065A1 (en) 2013-11-29
AU2012244748A1 (en) 2013-10-10
RU2013151087A (ru) 2015-05-27
JP2014519483A (ja) 2014-08-14
BR112013026539A2 (pt) 2016-12-27
EP2699113A1 (en) 2014-02-26
US20140056862A1 (en) 2014-02-27
CN103476275A (zh) 2013-12-25

Similar Documents

Publication Publication Date Title
BR112013026706A2 (pt) composições nutricionais compreendendo ácido alfa-hidroxi-isocaproico
BR112013026114A2 (pt) composições nutricionais que incluem ácidos graxos de cadeia ramificada e processos de utilização das mesmas
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
BR112012019924A2 (pt) polipeptídeos de ligação de agonista de dr5.
WO2012081982A3 (en) Whey protein composition with a reduced astringency
BR112014009265A8 (pt) micelas de proteína de soro do leite contra atrofia muscular e sarcopenia
MX2011010353A (es) Composicion farmaceutica.
MY173699A (en) Novel compounds for the treatment of diseases associated with amyloid of amyloid-like proteins
BR112014007069A2 (pt) proteínas de fusão para o tratamento de distúrbios metabólicos
EA201390827A1 (ru) Применение лаквинимода для уменьшения утомляемости, улучшения функционального состояния и улучшения качества жизни пациентов с рассеянным склерозом
EP4371615A3 (en) Treatment of amd using aav sflt-1
MX337830B (es) Peptidos utiles en el tratamiento y/o cuidado de la piel y/o cabello y su uso en composiciones cosmeticas o farmaceuticas.
BRPI1010830A2 (pt) Sequências de aminoácidos melhoradas direcionadas contra o vírus respiratório sencicial humano (hrsv) e polipetídeos que compreende os mesmos para prevenção e/ou tratamento de infecções do trato respiratório.
WO2008137758A3 (en) Amino acid lipids and uses thereof
BR112014008036A2 (pt) tratamento de rinite
BR112014008700A2 (pt) composições úteis no tratamento de nefropatia e processos para preparação das mesmas
WO2015183995A3 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
RU2017124487A (ru) НОВЫЙ ПЕПТИД-ИНГИБИТОР PI3Kγ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ОРГАНОВ ДЫХАНИЯ
NZ712713A (en) Attenuated swine influenza vaccines and methods of making and use thereof
WO2011121607A3 (en) Rasagiline and its pharmaceutically acceptable salts
MX2013006031A (es) Formulacion liposomal de dalcetrapib.
BR112014027213A8 (pt) nova composição de alfentanil para o tratamento de dor aguda
MX2011007108A (es) Incrementadores de angiogenesis generados por derrame cerebral y usos de los mismos.
MX350662B (es) Composiciones farmaceuticas que comprenden 7- (1h- imidazol-4-ilmetil) -5,6,7,8,-tetrahidroquinolina para el tratamiento de enfermedades y dolencias de la piel.
EA200801077A1 (ru) Антагонисты взаимодействия pf4 и rantes

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/7105 (2006.01), A23L 33/10 (2016.01), A23L

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2510 DE 12/02/2019.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.